Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients with Coronavirus Disease 2019

Ji-Won Kim, MD¹, Jun Sik Yoon, MD², Eun Jin Kim, MD³, Hyo-Lim Hong, MD⁴, Hyun Hee Kwon, MD⁴, Chi Young Jung, MD³, Kyung Chan Kim, MD³, Yu Sub Sung⁵, Sung-Hoon Park, MD¹, Seong-Kyu Kim, MD¹, Jung-Yoon Choe, MD¹

¹Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea
²Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
³Division of Pulmonology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea
⁴Division of Infectious Diseases, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea
⁵Clinical Research Center, Asan Medical Center, Seoul, Republic of Korea
⁶Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea

Correspondence to: Jung-Yoon Choe, MD, PhD

Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, 33, Duryugongwon-ro 17-gil, Nam-gu, Daegu 42472, Republic of Korea
(e-mail: jychoe@cu.ac.kr; phone: 82-53-650-4027)
Background: The impact of sarcopenia on clinical outcomes of coronavirus disease 2019 (COVID-19) is not clearly determined yet. We aimed to investigate the association between baseline sarcopenia and clinical outcomes in patients with COVID-19.

Methods: All hospitalized adult patients with COVID-19 who had baseline chest computed tomography (CT) scans at a Korean university hospital from February 2020 to May 2020 were included. The main outcome was time from hospital admission to discharge. Death was considered as a competing risk for discharge. Baseline skeletal muscle cross-sectional area at the level of the 12th thoracic vertebra was measured from chest CT scans. The lowest quartile of skeletal muscle index (skeletal muscle cross-sectional area divided by height-squared) was defined as sarcopenia.

Results: Of 121 patients (median age, 62 years; 44 men; 29 sarcopenic), 7 patients died and 86 patients were discharged during the 60-day follow-up. Patients with sarcopenia showed a longer time to discharge (median, 55 vs. 28 days; p<0.001) and a higher incidence of death (17.2% vs. 2.2%; p=0.004) than those without sarcopenia. Baseline sarcopenia was an independent predictor of delayed hospital discharge (adjusted hazard ratio [aHR], 0.47; 95% CI, 0.23-0.96), but was not independently associated with mortality in patients with COVID-19 (aHR, 3.80; 95% CI, 0.48-30.26). The association between baseline sarcopenia and delayed hospital discharge was consistent in subgroups stratified by age, sex, comorbidities, and severity of COVID-19.

Conclusion: Baseline sarcopenia was independently associated with prolonged hospital stay in patients with COVID-19. Sarcopenia could be a prognostic marker in COVID-19.

Keywords: COVID-19; severe acute respiratory syndrome coronavirus 2; sarcopenia; prognosis; length of stay
Introduction

In the absence of specific treatments for coronavirus disease 2019 (COVID-19), the COVID-19 pandemic has become a tremendous threat to human health worldwide. Most patients with COVID-19 experience mild to moderate disease, but some patients can develop severe respiratory illness and finally death. Older age, chronic comorbid conditions, and higher concentrations of d-dimer, interleukin-6, or C-reactive protein have all been associated with higher mortality in COVID-19 (1-6). However, factors associated with prolonged hospitalization in survivors of COVID-19 are not fully investigated. Because prolonged hospital stay increases the burden to public health under limited hospital resources, identifying these factors would be useful.

Sarcopenia is a muscle disorder characterized by low muscle strength combined with low muscle quantity or quality (7). Sarcopenia is highly associated with aging, but illness, malnutrition, and physical inactivity can also contribute to the development of sarcopenia (7). The adverse health effects of sarcopenia include poor quality of life, disability, and increased risk of falls, fractures, and hospitalization (8-10). In addition, the presence of sarcopenia is a proven predictor of treatment outcomes in patients with acute or chronic illness and those undergoing surgery (11-16). On computed tomography (CT), sarcopenia defined by the muscle mass at the level of the 3rd lumbar vertebra (L3) has predicted survival in patients with hepatocellular carcinoma and in liver transplant recipients (11, 12). CT-defined sarcopenia also predicted survival and length of intensive care unit (ICU) stay in patients requiring ICU admission after traumatic injuries (13).

CT is a useful tool for identifying sarcopenia by measuring muscle area in cross-sectional images, most commonly at the L3 level, which well represents the total body skeletal muscle mass (17, 18). The skeletal muscle mass can also be measured at the level of
the 12th thoracic vertebra (T12), which is highly correlated with the skeletal muscle mass at L3 and can also reflect clinical outcomes (19).

The association between sarcopenia and treatment outcomes in COVID-19 has not been examined. Therefore, we investigated the association between baseline sarcopenia and length of hospital stay and survival in hospitalized patients with COVID-19 by assessing for baseline sarcopenia using chest CT scans that were initially performed to evaluate COVID-19 pneumonia.

Methods

Patients

All patients with COVID-19 who were hospitalized at Daegu Catholic University Medical Center from February 17 to May 19, 2020 and had chest CT scans at baseline were eligible for this retrospective cohort study. Patients who did not have CT scans at baseline and those younger than 19 years were excluded from the study. The diagnosis of COVID-19 was based on positive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swab specimens. The study was approved by the Institutional Review Board of Daegu Catholic University Medical Center (CR-20-110). Informed consent was waived because of the retrospective study design.

Estimation of skeletal muscle index by chest computed tomography

Cross-sectional images were obtained from chest CT scans that were performed for evaluation of COVID-19 pneumonia at the time of admission. Cross-sectional areas of muscle and fat were measured from the axial CT image nearest to the inferior border of the T12 vertebral body by using AsanJ-Morphometry software (Seoul, South Korea), including erector spinae, external and internal oblique, latissimus dorsi, rectus abdominis, and external
and internal intercostal muscles. Tissue Hounsfield Unit (HU) thresholds were 0 to 100 HU for skeletal muscle and –190 to –30 HU for subcutaneous and visceral fat tissues. Total muscle area (cm$^2$) was determined after excluding the total intramuscular fat area (total intramuscular fat area = total fat area – subcutaneous fat area – visceral fat area; Figure 1). The skeletal muscle index (cm$^2$/m$^2$) was calculated as total muscle area adjusted for height. Sarcopenia was defined as the lowest quartile of skeletal muscle index, which was ≤24 cm$^2$/m$^2$ for men and ≤20 cm$^2$/m$^2$ for women. The reference values for sarcopenia were ≤29 cm$^2$/m$^2$ for men and ≤23 cm$^2$/m$^2$ for women in the COVID-19 survivors (for sensitivity analysis).

The muscle and fat areas were determined by two physicians (J.W.K. and J.S.Y.) who were blinded to the patients’ clinical information, and an intraclass correlation coefficient of 0.976 (95% confidence interval [CI], 0.959-0.986) indicated excellent reliability. We also selected 15 patients who had both chest and abdominal CT scans at baseline and confirmed a positive correlation between the measurements of the cross-sectional muscle areas at T12 and L3 (Spearman’s rho=0.732, p=0.003).

Main outcome and clinical parameters

Main outcome was time from hospital admission to discharge. Time to reaching study endpoint (discharge or death) was assessed until 60 days after admission. COVID-19 patients discharged alive are those who meet the criteria of 1) negative conversion of SARS-CoV-2 RNA from nasopharyngeal and oropharyngeal swabs (detection of two consecutive negative RT-PCR results), and 2) improvement of clinical symptoms and vital signs and/or resolution
of pneumonia. Most people who discharged met both the PCR-negative and clinical criteria for discharge within a week apart.

Data on age, sex, comorbidities (diabetes, hypertension, cardiovascular disease, chronic lung disease, and chronic kidney disease), duration of symptoms before admission, symptoms (cough, sputum, fever, dyspnea, diarrhea, etc.), oxygen support, chest CT findings, and laboratory values at baseline were obtained from the medical records. National Early Warning Score 2 (NEWS2, range 0 to 20) was determined from respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature at baseline (20). A higher score indicates greater clinical risk, with 0 to 4 = low risk; 5 to 6 = medium risk; and 7 or more = high risk. Data on treatment with antibiotics, glucocorticoids, or IV immunoglobulin, use of nasal prong, high-flow nasal cannula, or mechanical ventilation, and complications such as acute respiratory distress syndrome (ARDS) and shock were also collected retrospectively. ARDS was defined using the Berlin definition (21) and shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (22).

**Statistical analysis**

Comparison of two groups was conducted using Mann-Whitney U test for continuous variables and Chi-Square test or Fisher’s exact test for categorical variables. We executed a competing risk model for discharge outcome. Death was considered as a competing risk for discharge. Patients still hospitalized 60 days after admission and those who were transferred before study endpoint were censored. Cumulative incidence plots for discharge (or death) between patients with and without sarcopenia were drawn and compared by using Gray’s test.
The association between baseline sarcopenia and hospital discharge was investigated using a Fine and Gray proportional subdistribution hazards regression model. Subgroup analyses stratified by age, sex, comorbidities, disease severity, and treatment were also performed to estimate the predictive performance of sarcopenia on hospital discharge. All statistical analyses were performed using R software, version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient characteristics

Total 121 patients were included in this study after excluding 7 patients who did not have chest CT scans at baseline and 2 patients who were under the age of 19 (Figure 2).

Characteristics of the patients are described in Table 1. The median age was 62 years and 44 patients (36.4%) were men. The median duration of symptoms before admission was 7 (interquartile range [IQR], 3-10) days. Median NEWS2 at baseline was 2 (IQR, 1-5). Seventy patients (57.9%) had bilateral multifocal ground-glass opacities (GGOs) and/or consolidations on baseline chest CT images and 42 patients (34.7%) required oxygen support at baseline.

Of 121 patients, 29 patients (24%) met the study criteria for sarcopenia at baseline. Patients with sarcopenia presented with more severe disease at baseline, as indicated by higher NEWS2, more frequent oxygen support, and higher C-reactive protein (CRP) levels, than those without sarcopenia (Table 1). Sarcopenic individuals were older and had more frequent prevalence of hypertension and cardiovascular disease than those who were not sarcopenic. However, the duration of symptoms before admission and the presence of
bilateral multifocal GGOs and/or consolidations on baseline CT images did not differ
between patients with and without sarcopenia.

Seven patients (5.8%) died and 86 patients (71.1%) were discharged during the 60-
day period. Median length of hospital stay was 26 (IQR, 16-39) days. Characteristics of non-
survivors, survivors with prolonged hospital stay (length of hospital stay ≥26 days), and
survivors without prolonged hospital stay (length of hospital stay <26 days) are described in
**Supplementary Table S1.** Among 7 non-survivors, 5 patients (71.4%) were sarcopenic.
Sarcopenia was more common in patients with prolonged hospital stay than in patients
without prolonged hospital stay (28.8% vs. 12.7%; p = 0.035).

*Baseline sarcopenia as a predictor of length of hospital stay in COVID-19*

To determine whether baseline sarcopenia could predict the length of hospital stay,
cumulative incidence curves for discharge or death were depicted separately in patients with
and without sarcopenia (Figure 3). Patients with sarcopenia had significantly longer hospital
stay than those without sarcopenia (median, 55 vs. 28 days; Gray’s test, p <0.001). In
addition, patients with sarcopenia had a significantly higher death rate than those without
sarcopenia (17.2% vs. 2.2%; Gray’s test, p = 0.004).

Next, Fine and Gray proportional subdistribution hazards regression model for
competing risks was performed to determine whether baseline sarcopenia had an independent
effect on predicting length of hospital stay in patients with COVID-19 (Table 2). After
adjusting for age, sex, diabetes, hypertension, cardiovascular disease, chronic lung disease,
oxygen support at baseline, and CRP levels at baseline, baseline sarcopenia was significantly
associated with delayed hospital discharge (adjusted HR [aHR], 0.47; 95% CI, 0.23-0.96). In
addition, baseline sarcopenia tended to be associated with high mortality in patients with COVID-19, but without statistical significance (aHR, 3.80; 95% CI, 0.48-30.26). We then conducted additional analyses to determine whether sarcopenia was a consistent predictor of length of hospital stay in different subgroups (Supplementary Figure S1). Patients with sarcopenia at baseline were likely to experience delayed hospital discharge consistently in subgroups according to age, sex, comorbidities, disease severity, and steroid treatment.

Sensitivity analysis

For sensitivity analysis, we investigated the association between sarcopenia and length of hospital stay only in survivors of COVID-19 (excluding 7 non-survivors). Sarcopenia was an independent predictor of delayed hospital discharge after adjusting for age, sex, diabetes, hypertension, cardiovascular disease, chronic lung disease, oxygen support at baseline, and CRP levels at baseline (aHR, 0.60; 95% CI, 0.37-0.96), which was in line with the results from the primary analysis.

Discussion

The main question of this study was whether baseline sarcopenia was associated with the prognosis of COVID-19 in terms of length of hospital stay and survival. We used chest CT scans, which were performed to evaluate the presence and severity of pneumonia, to determine the presence of sarcopenia at baseline. Sarcopenia was an independent predictor of prolonged hospital stay in patients with COVID-19. The impact of sarcopenia on length of hospital stay was consistently observed in subgroups with regards to age, sex, comorbidities, and severity of COVID-19. In addition, sarcopenia tended to be associated with high
mortality in patients with COVID-19, although the association was not statistically significant due to small numbers of patients who died. Our analysis showed an association between baseline sarcopenia and prognosis in COVID-19.

The interplay between skeletal muscle and the immune system may validate the association between sarcopenia and the clinical course of COVID-19. Skeletal muscle is now regarded as an organ that can release multiple soluble factors (myokines) deriving autocrine and paracrine effects (23). Myokines not only induce muscle regeneration and homeostasis, but also maintain immune function. Interleukin (IL)-15 is a myokine that stimulates proliferation and activation of natural killer (NK) cells and CD8\(^+\) T lymphocytes and induces activation and phagocytosis of neutrophils (24, 25). NK cells and CD8\(^+\) T lymphocytes provide essential defense against viral pathogens, therefore, a lack of IL-15 signaling might contribute to poor immune responses against SARS-CoV-2. Indeed, defects in NK cells and CD8\(^+\) T lymphocytes and impaired antiviral responses have been observed in IL-15-deficient mice (26). Furthermore, impaired signaling of other myokines can cause a shift toward a proinflammatory environment (27, 28). Taken together, the integral role of skeletal muscle in immune function indicates that sarcopenia could be a prognostic factor in the treatment of COVID-19.

The association between sarcopenia and adverse outcomes of COVID-19 has been supported by other studies that examined CT-defined sarcopenia or clinical frailty scores in patients with COVID-19 (29-31). Low pectoralis muscle index (obtained by measuring the area of the pectoralis muscle on axial chest CT images) in patients with COVID-19 was associated with prolonged hospital stay and death (29). In a multi-center study in Europe, higher frailty scores in patients with COVID-19 were linked to higher mortality risk and longer duration of hospital stay compared with lower frailty scores (30). The presence of
diabetes, hypertension, and coronary artery disease was not associated with mortality or
duration of hospital stay, indicating that frailty is a better predictor of the clinical course of
COVID-19 than comorbidities (30). Our results, along with those of the other studies, suggest
that evaluating muscle area on chest CT can be a simple and useful tool for predicting
outcomes in patients with COVID-19.

Sarcopenia might also explain the heterogeneity of disease course in the context of
aging. Generally, increasing age is considered to be a prognostic factor in multiple diseases.
However, individually, age alone may have variable and inconsistent effects in predicting
clinical outcomes (32). Being old does not always mean being unhealthy, and conversely,
younger people may experience poor health-related outcomes (32). Sarcopenia, as well as
frailty, might be a latent prognostic factor which partially accounts for the heterogeneity of
associations between age and clinical outcomes (33). The clinical course of COVID-19 in
older patients with the disease differs according to their frailty status. Frail patients have a
higher mortality risk and experience severe disease more frequently than non-frail patients
(31, 34). Our study found that sarcopenia was a reliable marker of prolonged hospital stay in
a subgroup of older patients with COVID-19, confirming that not all older people have
similar outcomes in COVID-19. Sarcopenia and frailty also predict mortality in patients with
various other medical or surgical conditions, regardless of age (14, 35-37). Sarcopenia, which
reflects body composition better than body mass index, is a key physical component of frailty
(38). The present study demonstrated that baseline sarcopenia serves as a predictor of adverse
outcomes in COVID-19 independently of age.

There are some limitations of this study. First, our study was conducted within a
retrospective design. Further large, prospective study would be required to support our
findings. Second, sarcopenia was defined based on only muscle mass in our study, while the
current definition of sarcopenia is based on muscle mass and function (7). Third, reference values for sarcopenia measured from CT scans at thoracic levels are not determined in Korean population. However, cutoffs for height-adjusted cross-sectional area (skeletal muscle index) measured at the T12 level in our study population were quite similar to those in a healthy group in the United States (39). Fourth, we could not measure the skeletal muscle index at L3 across the study group because most of the patients had only chest CT scans. Instead, we checked the correlation between skeletal muscle indices from T12 and L3 levels in patients who had both chest and abdominal CT scans (n=15) and found a close relationship between them. Fifth, length of hospital stay might be influenced by several external factors such as social support, living environment, and services. However, we set the criteria for discharge in case of patients with COVID-19 (aforementioned in the methods section), and most patients followed these criteria. To overcome this possible limitation, mortality risk, as well as length of hospital stay, was evaluated in our study, because both mortality and hospital discharge are commonly selected outcomes in clinical studies of COVID-19 (3, 29, 30).

In conclusion, baseline sarcopenia was independently associated with duration of hospital stay in hospitalized patients with COVID-19. Patients with sarcopenia had increased mortality, but the association was not statistically significant. Although chest CT was originally conducted to evaluate the presence and severity of pneumonia in patients with COVID-19, it provided an additional value to assess for sarcopenia, which is a prognostic marker of COVID-19.
Acknowledgments

Author Contributions: J.W.K. and J.Y.C. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: J.W.K. and J.S.Y. Acquisition of data: J.W.K., E.J.K., H.L.H., H.H.K., C.Y.J., K.C.K. Analysis and interpretation of data: J.W.K. and J.S.Y. Drafting of the manuscript: J.W.K. Critical revision of the manuscript for important intellectual content: J.W.K., J.S.Y., and J.Y.C. Statistical analysis: J.W.K. and J.S.Y. Software: Y.S.S. Supervision: S.H.P. and S.K.K.

We thank all doctors, nurses, and healthcare professionals who participated in the care for patients with COVID-19 at Daegu Catholic University Medical Center.

Conflict of interest

All authors declare that they have no conflict of interest.

Funding

This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2019R1G1A1100421 to Ji-Won Kim).
References

1. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;395:1763-1770. doi: 10.1016/s0140-6736(20)31189-2

2. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *Bmj* 2020;369:m1985. doi: 10.1136/bmj.m1985

3. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *Bmj* 2020;369:m1966. doi: 10.1136/bmj.m1966

4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020. doi: 10.1001/jamainternmed.2020.0994

5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8:475-481. doi: 10.1016/s2213-2600(20)30079-5

6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-1062. doi: 10.1016/s0140-6736(20)30566-3

7. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;48:16-31. doi: 10.1093/ageing/afy169

8. Beaudart C, Biver E, Reginster JY, et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. *J Cachexia Sarcopenia Muscle* 2017;8:238-244. doi: 10.1002/jcsm.12149
9. Bianchi L, Ferrucci L, Cherubini A, et al. The Predictive Value of the EWGSOP Definition of Sarcopenia: Results From the InCHIANTI Study. *J Gerontol A Biol Sci Med Sci* 2016;71:259-264. doi: 10.1093/gerona/glv129

10. Scott D, Seibel M, Cumming R, et al. Sarcopenic Obesity and Its Temporal Associations With Changes in Bone Mineral Density, Incident Falls, and Fractures in Older Men: The Concord Health and Ageing in Men Project. *J Bone Miner Res* 2017;32:575-583. doi: 10.1002/jbmr.3016

11. Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. *J Hepatol* 2015;63:131-140. doi: 10.1016/j.jhep.2015.02.031

12. Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. *J Cachexia Sarcopenia Muscle* 2017;8:113-121. doi: 10.1002/jcsm.12095

13. Moisey LL, Mourtzakis M, Cotton BA, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. *Crit Care* 2013;17:R206. doi: 10.1186/cc12901

14. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer. *J Thorac Oncol* 2015;10:1795-1799. doi: 10.1097/jto.0000000000000690

15. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. *Eur J Cancer* 2016;57:58-67. doi: 10.1016/j.ejca.2015.12.030

16. Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. *Clin Nutr* 2018;37:1101-1113. doi: 10.1016/j.clnu.2017.07.010
17. Schweitzer L, Geisler C, Pourhassan M, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? *Am J Clin Nutr* 2015;102:58-65. doi: 10.3945/ajcn.115.111203

18. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol (1985)* 2004;97:2333-2338. doi: 10.1152/japplphysiol.00744.2004

19. Nemec U, Heidinger B, Sokas C, Chu L, Eisenberg RL. Diagnosing Sarcopenia on Thoracic Computed Tomography: Quantitative Assessment of Skeletal Muscle Mass in Patients Undergoing Transcatheter Aortic Valve Replacement. *Acad Radiol* 2017;24:1154-1161. doi: 10.1016/j.acra.2017.02.008

20. Royal College of Physicians. National Early Warning Score (NEWS) 2. [cited 2020 July 10]. Available from: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2.

21. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. *Jama* 2012;307:2526-2533. doi: 10.1001/jama.2012.5669

22. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016;315:801-810. doi: 10.1001/jama.2016.0287

23. Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. *EBioMedicine* 2019;49:381-388. doi: 10.1016/j.ebiom.2019.10.034

24. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *J Clin Oncol* 2015;33:74-82. doi: 10.1200/jco.2014.57.3329
25. Girard D, Paquet ME, Paquin R, Beaulieu AD. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. *Blood* 1996;88:3176-3184. doi:
26. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. *J Exp Med* 2000;191:771-780. doi: 10.1084/jem.191.5.771
27. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. *Faseb J* 2003;17:884-886. doi: 10.1096/fj.02-0670fje
28. Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. *Am J Physiol Endocrinol Metab* 2003;285:E433-437. doi: 10.1152/ajpendo.00074.2003
29. Ufuk F, Demirci M, Sagtas E, Akbudak IH, Ugurlu E, Sari T. The prognostic value of pneumonia severity score and pectoralis muscle Area on chest CT in adult COVID-19 patients. *Eur J Radiol* 2020;131:109271. doi: 10.1016/j.ejrad.2020.109271
30. Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. *Lancet Public Health* 2020;5:e444-e451. doi: 10.1016/s2468-2667(20)30146-8
31. Aw D, Woodrow L, Ogliari G, Harwood R. Association of frailty with mortality in older inpatients with Covid-19: a cohort study. *Age Ageing* 2020;49:915-922. doi: 10.1093/ageing/afaa184
32. Lowsky DJ, Olshansky SJ, Bhattacharya J, Goldman DP. Heterogeneity in healthy aging. *J Gerontol A Biol Sci Med Sci* 2014;69:640-649. doi: 10.1093/gerona/glt162
33. Schuurmans H, Steverink N, Lindenberg S, Frieswijk N, Slaets JP. Old or frail: what tells us more? *J Gerontol A Biol Sci Med Sci* 2004;59:M962-965. doi:
34. Ma Y, Hou L, Yang X, et al. The association between frailty and severe disease among COVID-19 patients aged over 60 years in China: a prospective cohort study. *BMC Med* 2020;18:274. doi: 10.1186/s12916-020-01761-0

35. Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from iISIRENTE study. *Age Ageing* 2013;42:203-209. doi: 10.1093/ageing/afs194

36. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. *Lancet Public Health* 2018;3:e323-e332. doi: 10.1016/s2468-2667(18)30091-4

37. Hewitt J, Carter B, McCarthy K, et al. Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational study. *Age Ageing* 2019;48:388-394. doi: 10.1093/ageing/afy217

38. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146-156. doi: 10.1093/gerona/56.3.m146

39. Derstine BA, Holcombe SA, Goulson RL, et al. Quantifying Sarcopenia Reference Values Using Lumbar and Thoracic Muscle Areas in a Healthy Population. *J Nutr Health Aging* 2017;21:180-185. doi: 10.1007/s12603-017-0983-3
Table 1 Characteristics of the patients with and without sarcopenia

| Variables                                           | Total (n = 121) | Sarcopenia<sup>a,b</sup> (n = 29) | No sarcopenia<sup>a,b</sup> (n = 92) | P value<sup>a</sup> |
|-----------------------------------------------------|-----------------|-----------------------------------|-------------------------------------|---------------------|
| Age, median (IQR), y                                | 62.0 (49.0;75.0) | 80.0 (72.0;83.0)                  | 57.5 (46.0;69.0)                  | <0.001              |
| Male sex, No. (%)                                   | 44 (36.4)       | 11 (37.9)                         | 33 (35.9)                         | 0.841               |
| Comorbidities, No. (%)                              |                 |                                   |                                    |                     |
| Diabetes                                            | 24 (19.8)       | 5 (17.2)                          | 19 (20.7)                         | 0.893               |
| Hypertension                                        | 30 (24.8)       | 12 (41.4)                         | 18 (19.6)                         | 0.034               |
| Cardiovascular disease<sup>c</sup>                  | 24 (19.8)       | 11 (37.9)                         | 13 (14.1)                         | 0.011               |
| Chronic lung disease<sup>d</sup>                    | 21 (17.4)       | 8 (27.6)                          | 13 (14.1)                         | 0.165               |
| Chronic kidney disease                              | 9 (7.4)         | 3 (10.3)                          | 6 (6.5)                           | 0.781               |
| Duration of symptoms before admission, median (IQR), d | 7.0 (3.0;10.0)  | 6.0 (2.0;10.0)                    | 7.0 (4.0;10.0)                    | 0.492               |
| Symptoms, No. (%)                                   |                 |                                   |                                    |                     |
| Cough                                               | 93 (76.9)       | 21 (72.4)                         | 72 (78.3)                         | 0.690               |
| Fever                                               | 81 (67.5)       | 20 (69.0)                         | 61 (67.0)                         | 1.000               |
| Sputum                                              | 74 (61.2)       | 16 (55.2)                         | 58 (63.0)                         | 0.589               |
| Dyspnea                                             | 67 (55.4)       | 21 (72.4)                         | 46 (50.0)                         | 0.057               |
| Diarrhea                                            | 41 (34.2)       | 9 (31.0)                          | 32 (35.2)                         | 0.854               |
| Myalgia                                             | 28 (23.3)       | 3 (10.3)                          | 25 (27.5)                         | 0.100               |
| Sore throat                                         | 25 (20.8)       | 3 (10.3)                          | 22 (24.2)                         | 0.182               |
| Rhinorrhea                                          | 21 (17.5)       | 5 (17.2)                          | 16 (17.6)                         | 1.000               |
| Chest pain                                          | 16 (13.3)       | 5 (17.2)                          | 11 (12.1)                         | 0.691               |
| NEWS2 at baseline, median (IQR)                     | 2.0 (1.0;5.0)   | 5.0 (2.0;9.0)                     | 2.0 (0.0;4.0)                     | <0.001              |
| Oxygen support at baseline, No. (%)                 | 42 (34.7)       | 17 (58.6)                         | 25 (27.2)                         | 0.004               |
| Bilateral multifocal GGOs and/or consolidations on baseline chest CT images, No. (%) | 70 (57.9) | 16 (55.2) | 54 (58.7) | 0.905 |
| Laboratory values at baseline, median (IQR)         |                 |                                   |                                    |                     |
| White blood cell count, /μL                         | 5300 (4300;6400) | 6300 (4600;7800)                  | 5200 (4100;6050)                  | 0.010               |
| Lymphocyte count, /μL                               | 1153.4          | 889.0                             | 1215.7                             | 0.001               |
| C-reactive protein, mg/L                            | 13.8 (1.0;48.2) | 38.2 (10.6;70.7)                  | 7.1 (0.8;31.1)                     | 0.005               |
| Aspartate aminotransferase, U/L                     | 24.0 (18.0;34.0) | 26.0 (18.0;36.0)                  | 24.0 (18.0;32.5)                  | 0.766               |
| Alanine aminotransferase, U/L | 18.0 (13.0;28.0) | 16.0 (11.0;22.0) | 19.0 (13.5;28.0) | 0.129 |
|-------------------------------|------------------|------------------|------------------|-------|
| Serum creatinine, mg/dL       | 0.7 (0.7;0.9)    | 0.7 (0.6;0.9)    | 0.8 (0.7;0.9)    | 0.174 |
| Concomitant treatment, No. (%)|                  |                  |                  |       |
| Antibiotic agent              | 94 (77.7)        | 27 (93.1)        | 67 (72.8)        | 0.042 |
| Glucocorticoid                | 20 (16.5)        | 10 (34.5)        | 10 (10.9)        | 0.007 |
| IV immunoglobulin             | 17 (14.0)        | 7 (24.1)         | 10 (10.9)        | 0.137 |
| Nasal prong                   | 53 (43.8)        | 17 (58.6)        | 36 (39.1)        | 0.103 |
| HFNC                          | 14 (11.6)        | 8 (27.6)         | 6 (6.5)          | 0.006 |
| MV                            | 8 (6.6)          | 3 (10.3)         | 5 (5.4)          | 0.618 |
| Complications, No. (%)        |                  |                  |                  |       |
| ARDS                          | 14 (11.6)        | 8 (27.6)         | 6 (6.5)          | 0.006 |
| Shock                         | 7 (5.8)          | 3 (10.3)         | 4 (4.3)          | 0.453 |
| ICU stay                      | 10 (8.3)         | 4 (13.8)         | 6 (6.5)          | 0.393 |

NEWS2, national early warning score 2; GGO, grand-glass opacity; CT, computed tomography; IV, intravenous; HFNC, high-flow nasal cannula; MV, mechanical ventilation; ARDS, acute respiratory distress syndrome; ICU, intensive care unit.

*Values are compared between patients with and without sarcopenia using Mann-Whitney U test, Chi-square test, or Fisher’s exact test, as appropriate.

*Sarcopenia was defined as the lowest quartile of skeletal muscle index at the level of the 12th thoracic vertebra.

Cardiovascular disease includes ischemic heart disease, heart failure, valvular heart disease, arrhythmia, and cerebrovascular accident.

Chronic lung disease includes asthma, chronic obstructive pulmonary disease, interstitial lung disease, lung cancer, and tuberculosis-associated lung damage.
Table 2 Baseline sarcopenia as a predictor of delayed hospital discharge and death in COVID-19

| Outcome                  | No. of events/No. of population | Incidence rate | Unadjusted HR (95% CI)\(^a\) | Adjusted HR (95% CI)\(^a,b\) |
|--------------------------|---------------------------------|----------------|-------------------------------|------------------------------|
| Discharge at day 60      |                                 |                |                               |                              |
| Sarcopenia               | 14/29                           | 48.3%          | 0.34 (0.18-0.64)              | 0.47 (0.23-0.96)             |
| No sarcopenia            | 72/92                           | 78.3%          | Reference                     | Reference                    |
| Death at day 60          |                                 |                |                               |                              |
| Sarcopenia               | 5/29                            | 17.2%          | 6.25 (1.18-33.04)             | 3.80 (0.48-30.26)            |
| No sarcopenia            | 2/92                            | 2.2%           | Reference                     | Reference                    |

HR, hazard ratio; CI, confidence interval.

\(^a\)HRs were determined using the Fine and Gray proportional subdistribution hazards regression model for competing risks.

\(^b\)Adjusted for age, sex, diabetes, hypertension, cardiovascular disease, chronic lung disease, oxygen support at baseline, and CRP at baseline.
Figure legends

Figure 1 Measurement of muscle area on axial CT images at the level of the 12th thoracic vertebra in (A) non-sarcopenic and (B) sarcopenic COVID-19 patients with the same BMI. The purple area represents the skeletal muscle. The skeletal muscle indices are 37.1 cm^2/m^2 and 15.5 cm^2/m^2 for patients A and B, respectively. The lower density of the purple area (patient B) indicates the smaller skeletal muscle area.

Figure 2 Flow chart of the study population

*aSarcopenia was defined as the lowest quartile of skeletal muscle index at the level of the 12th thoracic vertebra.

Figure 3 Cumulative incidence curves indicating the rate of discharge or death in accordance with absence or presence of sarcopenia in patients with COVID-19.
Figure 1
Figure 2

130 Participants hospitalized for COVID-19 at Daegu Catholic University Medical Center from Feb 17 to May 19, 2020

- 9 Were excluded
- 7 Did not have chest CT scans at baseline
- 2 With age <19 years

121 Participants eligible for the study

29 Had sarcopenia* at baseline
92 Did not have sarcopenia at baseline
